JPRN-jRCT2032230595招募中3 期
A multicenter randomised open-label study to evaluate the efficacy and safety of the digital therapeutics CA-NASH in patients with Nonalcoholic Steatohepatitis (NASH) (Phase 3)
echi Tatsuya0 个研究点目标入组 346 人开始时间: 2024年1月26日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 346
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Subjects who meet all of the following criteria will be included.
- •(1) 18 years of age or older at the time of the consent.
- •(2) Able to understand and give written informed consent.
- •(3) Have a diagnosis of NASH and meet all of the following criteria
- •Body mass index (BMI) >=25.0 kg/m2 (Including BMI >=35.0 kg/m2)
- •Recommended weight loss through the guidance for lifestyle improvement
- •(4)Use smartphone with iOS 16 or higher or Android version 10 or higher.
- •(5)Able to fully understand the content of CA-NASH and use the smartphone application.
排除标准
- •Subjects who meet any of the following criteria shall not be included in this study.
- •(1) Subjects with a positive HBs antigen or HCV-RNA result at screening. Or patients with a positive HBs antigen or HCV-RNA test result within 2 years prior to the screening.
- •(2) Subjects with autoimmune hepatitis, primary cholangitis, or primary sclerosing cholangitis.
- •(3) Subjects with metabolic diseases such as hemochromatosis and Wilson's disease (if already diagnosed by ceruloplasmin, alfa1-antitrypsin, transferrin saturation, etc.).
- •(4) Subjects with liver cirrhosis or suspected liver cirrhosis.
- •(5) Coexisting hepatocellular carcinoma or have a history of treatment for hepatocellular carcinoma.
- •(6) History of diagnosis and treatment of malignant tumors within 5 years prior to the consent (excluding cancers that can be cured by local treatment, such as basal cell cancer, squamous cell carcinoma, and intraepithelial carcinoma).
- •(7) Subjects with secondary NASH (NASH associated with steroids and tamoxifen, NASH associated with endocrine disorders, NASH due to polycystic ovary syndrome, etc.).
- •(8) Subjects with portal hypertension or signs of hepatic insufficiency (ascites accumulation, variceal hemorrhage, idiopathic bacterial peritonitis, hepatic encephalopathy) or with a history of such complications.
- •(9) History of getting a liver transplant as a recipient.
- •(10) Have a habit of drinking more than 20 g/day (pure ethanol equivalent) for women and 30 g/day (pure ethanol equivalent) for men.
- •(11) Subjects who have been newly prescribed/changed the dosage of/ discontinued vitamin E, pioglitazone, SGLT2 inhibitors, GLP-1 receptor agonists, Mazindol, HMG-CoA reductase inhibitors, pemafibrate, ezetimibe, angiotensin II receptor blockers (ARB), ACE inhibitors, Bofu Tongsang, or Oshibagoto within 90 days prior to consent.
- •(12) History of undergoing or scheduled to undergo bariatric surgery.
- •(13) Subjects who cannot be safely performed the liver biopsy (platelet count of less than 10 x 10-4/microliter or prothrombin time of less than 70%, etc. within 180 days prior to consent or visit 1).
- •(14) Pregnant, lactating, or female subjects who wish to get pregnant during the study period.
- •(15) Subjects who have received interventions in other clinical trials within 90 days prior to consent.
- •(16) Subjects who have previously participated in a the clinical trial (Ph-2 study) of this product.
- •(17) Judged to be inappropriate as a participant by the investigator or subinvestigator.
研究者
相似试验
招募中
1 期
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and how Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.MedDRA version: 21.0Level: PTClassification code: 10059176Term: Juvenile idiopathic arthritis Class: 100000004859juvenile idiopathic arthritisCTIS2022-501599-25-00Abbvie Deutschland GmbH & Co. KG90
进行中（未招募）
1 期
Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsEUCTR2020-002037-15-ESCristina Avendaño Sola200
已完成
2 期
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cyclescontraceptionFertility controlNL-OMON34076Bayer110
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsPrevention of PregnancyMedDRA version: 12.1Level: LLTClassification code 10060346Term: Transdermal contraceptionEUCTR2010-021255-81-NLBayer HealthCare AG174
进行中（未招募）
不适用
Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles - Inhibition of ovulation and pharmacokinetic study of 3 transdermal EE and GSD formulationsEUCTR2010-021255-81-DEBayer HealthCare AG174